ArticleThe World Allergy Organization journal2026
The shifting landscape of asthma in the United States: An over 20-year analysis of prevalence, severity, and medication paradigms, 1999-2023.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma remains a substantial public health burden in the United States, warranting updated estimates of prevalence, morbidity, and medication use across population subgroups. Methods: This study analyzed data from 114,505 participants in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2023. Asthma status (lifetime, current, attack, emergency visit) and medication use were assessed through self-reports and prescription data. Weighted prevalence trends were evaluated across demographic subgroups. Results: Among 114,505 participants (median age 37 years; 51.2% male) in NHANES 1999-2023, the prevalence of lifetime and current asthma was 14.7% and 8.8%, respectively. Lifetime asthma prevalence increased from 11.2% to 15.8%, and current asthma from 6.5% to 9.3%, by 0.41% (95%CI: 0.28 to 0.54) and 0.24% (0.09-0.38) per NHANES cycle, respectively. Prevalence was consistently higher in women, non-Hispanic Black individuals, and those with lower socioeconomic status. Adolescents had the highest lifetime asthma prevalence (19.3%). Asthma attacks and emergency visits among those with current asthma declined significantly, by -0.99% (-1.94 to -0.03) and -1.94% (-2.96 to -0.93) per NHANES cycle, respectively. During the study period, the prevalence of asthma medication use showed a biphasic trend: an overall increase from 1999 to 2000 to a peak in 2007-2008, followed by a significant decline through 2020-2023. Lower education and income levels were associated with higher medication usage. Conclusion: Over the past 2 decades, asthma prevalence increased at the population level, whereas the prevalence of asthma attacks and asthma-related emergency visits among individuals with current asthma declined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.